• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ETHICON INC. SURGICEL FIBRILLAR 1INX2IN(2.5CMX5.1CM); AGENT, ABSORBABLE HEMOSTATIC, NON-COLLAGEN BASED

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ETHICON INC. SURGICEL FIBRILLAR 1INX2IN(2.5CMX5.1CM); AGENT, ABSORBABLE HEMOSTATIC, NON-COLLAGEN BASED Back to Search Results
Catalog Number 1961
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Codes Unspecified Infection (1930); Pain (1994)
Date of Event 02/17/2025
Type of Reportable Event Serious Injury
Event or Problem Description
It was reported that a patient underwent a left total knee arthroplasty procedure on (b)(6) 2025 and absorbable hemostat was used.The patient was admitted to the hospital and completed relevant examinations.After excluding surgical contraindications, the surgery was performed from 9:15 to 10:24, and hemostatic gauze was used during the surgery.No abnormalities were found during the use process, the placement was smooth, and the patient was discharged after the surgery and followed up regularly.307 days after the surgery, the patient was admitted to the hospital for postoperative wound infection of the knee joint.The patient's left knee joint had good range of motion, but there was still intermittent pain.After the patient was admitted to the hospital, relevant examinations were completed, and the left knee joint was punctured and fluid was drawn for bacterial culture and identification, indicating dysgalactiae streptococcus infection.The patient's imaging examination showed the formation of a translucent zone around the prosthesis, which was consistent with signs of infectious loosening of the prosthesis, and surgery was performed.Postoperative sequential anti-infection, local injection, nutritional support, symptomatic support and other treatments.Additional information was requested.
 
Additional Manufacturer Narrative
Product complaint # (b)(4) h6.Component code: g07002 - device not returned.To date the device has not been returned.If the device or further details are received at a later date a supplemental medwatch will be sent.Additional information was requested, and the following was obtained: the second procedure should be debridement surgery, removal of left knee prosthesis, joint revision surgery.Attempts are being made to obtain the following information.To date no response has been provided.If further details are received at a later date a supplemental medwatch will be sent.1.Please provide the following patient demographic information, if available: age, gender, weight, bmi at the time of index procedure? 2.What were the diagnosis and indication for the index surgical procedure? 3.Please provide any relevant patient history: patient pre-existing medical conditions (i.E.Allergies, history of reactions), all concomitant medications, past medical history, any treatment required for events, dose, frequency, and therapy dates.4.Was there any intraoperative concurrent use of other products? 5.What was the intended use of the surgicel? was it used to address active bleeding or used prophylactically? 6.Where was the surgicel used (on what tissue)? 7.What method was used when applying the surgicel? 8.How much surgicel was used during the procedure? 9.Provide a detailed description of how the wound was closed during the initial surgery.10.What were current symptoms following the index surgical procedure? onset date? 11.Has any additional surgical or medical intervention been performed? 12.What is physician¿s opinion as to the cause of this event? 13.Was there an alleged deficiency of the surgicel that contributed to the patient¿s post-operative events? 14.What is the patient¿s current status? 15.What is the users experience w/ surgicel powder and other hemostatic agents? this report is being submitted pursuant to the provisions of 21 cfr part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
 
Additional Manufacturer Narrative
Product complaint # (b)(4).Additional information: h6.Type of investigation.Additional information was requested, and the following was obtained: contacted with the sales rep today via phone, please refer to the event description.Other information requested is unknown.The following information was requested, but unavailable: 1.Please provide the following patient demographic information, if available: age, gender, weight, bmi at the time of index procedure? 2.What were the diagnosis and indication for the index surgical procedure? 3.Please provide any relevant patient history: patient pre-existing medical conditions (i.E.Allergies, history of reactions), all concomitant medications, past medical history, any treatment required for events, dose, frequency, and therapy dates.4.Was there any intraoperative concurrent use of other products? 5.What was the intended use of the surgicel? was it used to address active bleeding or used prophylactically? 6.Where was the surgicel used (on what tissue)? 7.What method was used when applying the surgicel? 8.How much surgicel was used during the procedure? 9.Provide a detailed description of how the wound was closed during the initial surgery.10.What were current symptoms following the index surgical procedure? onset date? 11.Has any additional surgical or medical intervention been performed? 12.What is physician¿s opinion as to the cause of this event? 13.Was there an alleged deficiency of the surgicel that contributed to the patient¿s post-operative events? 14.What is the patient¿s current status? 15.What is the users experience w/ surgicel powder and other hemostatic agents? a manufacturing record evaluation was performed for the finished device batch and no non-conformances were identified.This report is being submitted pursuant to the provisions of 21 cfr part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SURGICEL FIBRILLAR 1INX2IN(2.5CMX5.1CM)
Common Device Name
AGENT, ABSORBABLE HEMOSTATIC, NON-COLLAGEN BASED
Manufacturer (Section D)
ETHICON INC.
1000 route 202
raritan NJ 08869
Manufacturer (Section G)
ETHICON INC.-SAN LORENZO PR
road 183, km 8.3
san lorenzo PR 00754
Manufacturer Contact
orla o'mahony
1000 route 202
raritan, NJ 08869
3035526892
MDR Report Key22038632
Report Number2210968-2025-05460
Device Sequence Number15489311
Product Code LMG
UDI-Device Identifier10705031003118
UDI-Public(01)10705031003118(17)260630(10)TKE3971
Combination Product (Y/N)N
Initial Reporter CountryCH
PMA/510(K) Number
N12159
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Other,Foreign,Health Professional
Initial Reporter Occupation Other
Type of Report Initial,Followup
Report Date (Section B) 05/22/2025
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date06/30/2026
Device Catalogue Number1961
Device Lot NumberTKE3971
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 05/09/2025
Supplement Date Received by Manufacturer05/19/2025
Initial Report FDA Received Date05/16/2025
Supplement Report FDA Received Date05/22/2025
Was Device Evaluated by Manufacturer? (Y/N) No
Date Device Manufactured07/06/2023
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient SexUnknown
-
-